Skip to content
New: free dose calculator with 14 peptide presets. No signup.
Peptides Academy
Oxytocin
Nasal Peptides

Oxytocin

Research-Grade

Oxytocin is a cyclic nonapeptide (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂) synthesized in the paraventricular and supraoptic nuclei of the hypothalamus and released from the posterior pituitary. It is one of the most thoroughly studied peptide hormones in medicine. Its classical functions — uterine contraction during labor and milk ejection during breastfeeding — led to FDA approval of synthetic oxytocin (Pitocin) for labor induction and postpartum hemorrhage. These remain its primary clinical applications. The modern research interest in oxytocin centers on its role in social cognition and behavior. Intranasal oxytocin administration has been studied in over 300 clinical trials for conditions including autism spectrum disorder (ASD), social anxiety disorder, PTSD, schizophrenia, and borderline personality disorder. Results have been mixed: early single-dose studies showed enhanced social attention, empathy, and trust, but larger RCTs have generally failed to show clinically meaningful long-term behavioral changes. The disconnect between acute laboratory effects and clinical efficacy has led to a more nuanced understanding. Oxytocin appears to modulate social salience rather than simply 'increasing trust' — it can enhance both prosocial and antisocial responses depending on context. Individual differences in endogenous oxytocin system tone, receptor polymorphisms, and attachment history influence response to exogenous administration.

Specifications

Origin / ManufacturerSynthetic (identical to endogenous)
Active Components
Oxytocin acetate
StorageStore at 2–8°C, protect from light
Shelf Life24 months (lyophilized)
Form FactorLyophilized powder; intranasal spray; IV solution (Pitocin)

Clinical Evidence

FDA-approved for labor induction and augmentation — decades of clinical use, well-characterized dose-response and safety profile

Clinical report reference

Intranasal oxytocin meta-analyses (Leppanen et al., 2017; Keech et al., 2018) show small acute effects on social cognition measures but inconsistent long-term clinical outcomes

Clinical report reference

SOAR trial (Sikich et al., 2021, NEJM): 24-week intranasal OT in ASD children (n=290) — no significant improvement in social functioning vs placebo

Clinical report reference

PTSD: small RCTs show enhanced fear extinction with single-dose OT, but no definitive therapeutic trial

Clinical report reference

Chronic intranasal use safety: well-tolerated in trials up to 12 weeks; long-term receptor desensitization is a theoretical concern

Clinical report reference

Frequently Asked Questions

Sources & References

Every clinical claim on this page traces to a primary peer-reviewed source.

  1. 1Sikich L, et al.. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. New England Journal of Medicine. 2021;385(16):1462-1473. doi:10.1056/NEJMoa2103583 PMID:34644471
  2. 2Leppanen J, et al.. Meta-analysis of the effects of intranasal oxytocin on interpretation and expression of emotions. Neuroscience & Biobehavioral Reviews. 2017;78:125-144. PMID:28442404
  3. 3Keech B, et al.. The Effects of Intranasal Oxytocin on Social Cognition: A Meta-analysis. Neuroscience & Biobehavioral Reviews. 2018;87:67-85.

Reviewed by

Clinical Research Review Board

Neuroendocrinology Review

All clinical claims cross-checked against primary sources. Read our editorial policy →

Related Peptides

Reviewed by Clinical Research Review BoardNeuroendocrinology Review

Search

Search across products, blog posts, wiki articles, and more.